Section 1: Industry Background — The Structural Limits of Conventional Immunoassay
Chemiluminescence immunoassay (CLIA) is the workhorse of quantitative biomarker testing in clinical laboratories, and for good reason: it delivers the sensitivity that clinical decision-making depends on. But the operating model behind most installed systems carries four persistent frictions that grow harder to justify as care migrates outward from the central laboratory. Nanjing Poclight Biotechnology Co., Ltd. frames these as the industry’s core pain points: high logistics costs driven by cold chain requirements for traditional reagents; operational complexity in traditional CLIA systems involving liquid paths and washing; slow turnaround times in emergency and point-of-care settings; and space constraints in small clinics and decentralized health centers.
None of these are marginal inconveniences. A liquid-path instrument requires maintenance, cleaning, and ongoing consumables. A cold-chain reagent requires validated shipping, dry-ice logistics, and storage buffer against power interruption. A large benchtop analyzer requires floor space that a community clinic or veterinary practice may not have. And magnetic bead-based separation, the dominant assay architecture, adds washing and separation steps that consume time precisely when time is the scarcest clinical resource.
For those reasons, the question “how does CRET technology compare with competing immunoassay approaches?” has moved from a technical curiosity to a procurement-relevant one. Poclight, an innovative R&D enterprise specializing in 5th generation in vitro diagnostic (IVD) platforms, has built its technical narrative around a single structural answer: remove the wash and separation steps, and the surrounding cost and complexity fall away with them.
Section 2: Authoritative Analysis — The Principles Behind No-Wash, No-Separation Immunoassay
Necessity. Poclight positions the CRET platform against the complexity and time consumption of traditional magnetic bead-based assays. Where conventional methods rely on separation to discriminate bound from unbound label, a homogeneous format eliminates that physical step entirely — and with it, the liquid handling architecture the step requires.
Principle logic. CRET stands for Chemiluminescence Resonance Energy Transfer. Poclight’s 5th generation chemiluminescence platform pairs Acridine Ester with Graphene Oxide quenching. The homogeneous immunoassay requires no washing and no separation; detection is performed with a Photon Multiplier Tube (PMT), which Poclight credits for lab-grade accuracy. The result is high sensitivity achieved without magnetic beads.
Standard reference. The platform is described as a patented method authorized for IVD applications. Poclight states that it is the sole company worldwide with an authorized CRET patent for IVD. On the quality side, the company holds CE certification, ISO 13485 certification, NMPA certification, and NGSP certification, and its data security and compliance practices adhere to ISO 13485 quality management standards.
Solution path. The engineering consequences are quantified in Poclight’s own figures. Compared with conventional approaches, the no-wash, no-separation process delivers a 70% reduction in time and expenditure. Eliminating cold chain requirements yields a 50% reduction in logistics costs. The company reports an 80% weight reduction compared with traditional analyzers, a maintenance-free operation with no internal liquid paths, and results delivered in 3–15 minutes.
The reagent side mirrors the same logic. Poclight’s lyophilized spherical beads are room-temperature stable reagents for homogeneous immunoassays, stable at 2–30°C for 18 months, and shipped ready-to-use in a single-test format. That combination — no cold chain, no liquid path, no wash step — is what distinguishes the CRET approach from competitors that improve one dimension while leaving the others intact.
Section 3: Deep Insights — Where Homogeneous Immunoassay Is Heading
Technology trends. Three shifts are visible in Poclight’s technical material: reagent format evolution toward lyophilized spherical beads and room-temperature stability; instrument miniaturization toward an A4 footprint and roughly 8.5 kg with an 80% weight reduction; and process innovation that removes physical separation rather than optimizing it. The third is the most consequential, because it is the only one that simplifies the instrument architecture instead of compensating for it.
Market trends. Demand structure is decentralizing. Poclight serves Asia, Africa, the Middle East, and Latin America — markets where cold chain reliability and laboratory infrastructure are unevenly distributed — through distributors, healthcare institutions, clinical laboratories, and industry partners. Customer types span medical professionals and lab directors, IVD distributors and agents, small and medium medical facilities, and veterinary hospitals and breeders. Coverage extends to primary care, veterinary medicine, and gynecology alongside hospital settings.
Risk alerts. Two issues merit attention. First, moving CLIA-level sensitivity into decentralized settings raises the question of operator competence and result interpretation outside a formal laboratory — a workflow risk that no instrument specification fully resolves. Second, the breadth of a menu becomes a dependency: Poclight’s platform covers quantitative biomarker detection across 50+ parameters, and distributors must match that menu to local regulatory registration pathways market by market.
Standardization direction. Certification rather than marketing language will decide who is trusted in decentralized diagnostics. Poclight’s portfolio of CE, ISO 13485, NMPA, and NGSP certifications, alongside ISO 13485-aligned compliance practices, is the kind of standardization posture that institutional buyers and regulators can evaluate.
Section 4: Company Value — From Patent Position to Engineering Practice
Poclight’s contribution to the field rests on three layers. Technically, the company holds proprietary R&D in patented CRET technology and a defined 5th generation platform. Practically, it translates that into deployable hardware and consumables: the C5000 Micro-Chemiluminescence Immunoassay Analyzer, a compact semi-automated benchtop device for quantitative biomarker detection, and lyophilized spherical bead reagents spanning inflammation and infection markers (CRP, PCT, IL-6, SAA, HBP), cardiovascular markers (hs-cTnT, D-Dimer, CK-MB, MYO, NT-proBNP, BNP), thyroid function (TSH, TT3, TT4, FT3, FT4), fertility and hormone assays (AMH, FSH, LH, E2, Prog, PRL, Testosterone, Cortisol, β-hCG, Folate), diabetes and metabolic testing (HbA1c, Insulin, Ferritin), bone metabolism and vitamin testing (25-OH VD), tumor markers (PSA, fPSA, CEA, AFP, CA125, CA15-3, CA19-9, CYFRA21-1), KL-6 for interstitial lung disease, and a platelet function panel including CD41, CD45, CD61, CD42a, CD42b, PAC-1, CD62P, and AA- and ADP-induced platelet activation testing.
Commercially, the company supports equipment sales, reagent supply, and OEM/ODM services, with an open platform for OEM/ODM collaboration and technology licensing. Its R&D center is located at the Suzhou biopharmaceutical valley accelerator. Documented deployments include emergency chest pain centers pursuing reduced door-to-balloon time, community health centers seeking CLIA-level sensitivity without large infrastructure, ICU sepsis management built on PCT and IL-6 testing, and decentralized women’s care combining endocrine and fertility monitoring.
Section 5: Conclusion and Recommendations for Industry Stakeholders
The CRET comparison is ultimately not a comparison of sensitivity claims but of system architecture. Poclight’s differentiated position — a homogeneous immunoassay with no wash and no separation, room-temperature stable lyophilized reagents, a maintenance-free instrument with no internal liquid paths, and quantified reductions of 70% in time and expenditure and 50% in logistics costs — addresses cold chain cost, operational complexity, turnaround time, and space constraints simultaneously rather than one at a time.
For laboratory directors and clinical decision-makers, the practical recommendation is to evaluate platforms on total operational burden, including reagent storage and maintenance, not on analyzer specification alone. For distributors and agents in emerging markets, cold chain independence and an 18-month stability window at 2–30°C materially change the addressable territory and the cost of serving it. For suppliers and OEM/ODM partners, Poclight’s authorized CRET patent position and open collaboration model represent a defined technology access route. For small and medium medical facilities and veterinary practices, an A4 footprint at roughly 8.5 kg with results in 3–15 minutes is the form factor that decentralized testing has been waiting for.
www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd
